EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Safety and efficacy of intermittent fasting with or without exercise in people living with overweight or obesity and type 2 diabetes—The INTERFAST ‐3 study design

Caren Sourij, Alexander Müller, Abdullah Al-Baghdadi, Faisal Aziz, Norbert J Tripolt iD, Peter N Pferschy, Eva Andritz, Harald Kojzar, Vanessa Stadlbauer, Sabrina Leal Garcia, Harald Sourij

Diabetic Medicine · 2026-07 · 43 (7)

DOI: 10.1111/dme.70328 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetic Medicine, online erschienen am 15.04.2026. Verfasst von Caren Sourij und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Medical University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Caloric Restriction, Diabetes Mellitus, Type 2, Exercise Therapy, Intermittent Fasting. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Lifestyle modification, including caloric restriction and exercise, is fundamental in the treatment of people living with overweight and type 2 diabetes mellitus (T2D). The overall aim of lifestyle intervention schemes is to reduce body weight and improve glycaemic control to reduce the future risk of diabetes‐associated complications. The aim of this study is to determine whether intermittent energy restriction, exercise or their combination is best suited for reaching these targets in individuals with T2D not treated with insulin.

Methods

This randomized, controlled, monocentric parallel‐group trial is designed to investigate participants living with T2D, body mass index >27 kg/m 2 , HbA1c ≥53 mmol/mol (≥7.0%) and ≤86 mmol/mol (≤10.0%) and without insulin therapy. Participants are equally and randomly allocated to one of four study groups: (1) intermittent energy restriction group, (2) exercise group, (3) combined intermittent energy restriction and exercise group and (4) control group. The intervention phase lasts 12 weeks, followed by a two‐year follow‐up phase. In addition to assessing body weight and glycaemic parameters, resting energy expenditure (REE) and body composition are measured. An oral glucose tolerance test is carried out at baseline and at the end of the intervention. Additionally, stool samples for microbiome analyses and individual‐related outcomes are collected, and all participants are equipped with continuous glucose monitoring (CGM). The primary outcome measure is the change in bodyweight from baseline to day 84. Trial Registration The study was registered at DRKS (Deutsches Register Klinischer Studien—German Clinical Trial Register DRKS‐ID: DRKS00032036)—Date of registration: 11.10.2023.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Caloric RestrictionDiabetes Mellitus, Type 2Exercise TherapyIntermittent FastingObesityOverweightAdultFemaleHumansMaleMiddle AgedBlood GlucoseBody Mass IndexCombined Modality TherapyExerciseGlycated HemoglobinGlycemic ControlTreatment OutcomeWeight Loss

Stichwörter der Autor:innen

CGM (continuous glucose monitoring)exerciseintermittent energy restrictionintermittent fastinglifestyleobesitytype 2 diabetes mellitus

Substanzen

Blood GlucoseGlycated Hemoglobin

Autor:innen und Institutionen

  • Division of Cardiology, Medical University of Graz, Graz, Austria.
  • Cardiometabolic Trials Unit, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
  • Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria.
  • Department for Medical Psychology, Psychosomatic and Psychotherapy, Medical University of Graz, Graz, Austria.

ORCID-Profile: Norbert J Tripolt

Förderung

  • Austrian Science Fund

Zitieren

APA

Sourij, C., Müller, A., Al-Baghdadi, A., Aziz, F., Tripolt, N. J., Pferschy, P. N., Andritz, E., Kojzar, H., Stadlbauer, V., Garcia, S. L., & Sourij, H. (2026). Safety and efficacy of intermittent fasting with or without exercise in people living with overweight or obesity and type 2 diabetes—The INTERFAST ‐3 study design. Diabetic Medicine, 43(7). https://doi.org/10.1111/dme.70328

Vancouver

Sourij C, Müller A, Al-Baghdadi A, Aziz F, Tripolt NJ, Pferschy PN, et al. Safety and efficacy of intermittent fasting with or without exercise in people living with overweight or obesity and type 2 diabetes—The INTERFAST ‐3 study design. Diabetic Medicine. 2026;43(7). doi:10.1111/dme.70328

BibTeX
@article{Sourij2026,
  author = {Sourij, Caren and Müller, Alexander and Al-Baghdadi, Abdullah and Aziz, Faisal and Tripolt, Norbert J and Pferschy, Peter N and Andritz, Eva and Kojzar, Harald and Stadlbauer, Vanessa and Garcia, Sabrina Leal and Sourij, Harald},
  title = {Safety and efficacy of intermittent fasting with or without exercise in people living with overweight or obesity and type 2 diabetes—The INTERFAST ‐3 study design},
  journal = {Diabetic Medicine},
  year = {2026},
  volume = {43},
  number = {7},
  doi = {10.1111/dme.70328}
}
Kostenlos starten →